Aydin Huseynov
Stock Analyst at Ladenburg Thalmann
(0.69)
# 3,793
Out of 4,761 analysts
57
Total ratings
29.17%
Success rate
-23.89%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Aydin Huseynov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| URGN UroGen Pharma | Assumes: Buy | $31 | $10.08 | +207.54% | 1 | Feb 19, 2025 | |
| MRKR Marker Therapeutics | Maintains: Buy | $11 → $19 | $1.57 | +1,110.19% | 2 | Oct 21, 2024 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $12 → $21 | $4.19 | +401.19% | 3 | Sep 16, 2024 | |
| CMPX Compass Therapeutics | Upgrades: Buy | $5 | $2.92 | +71.23% | 2 | Sep 16, 2024 | |
| ACRV Acrivon Therapeutics | Upgrades: Buy | $16 | $5.54 | +188.81% | 3 | Sep 16, 2024 | |
| CLDI Calidi Biotherapeutics | Initiates: Buy | $10 | $1.05 | +852.38% | 1 | Jun 27, 2024 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $24 → $25 | $15.00 | +66.67% | 2 | May 14, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Neutral | n/a | $0.42 | - | 3 | Mar 14, 2024 | |
| BDRX Biodexa Pharmaceuticals | Initiates: Buy | $200 | $3.71 | +5,290.84% | 1 | Feb 8, 2024 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $7 | $1.41 | +396.45% | 1 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.40 | +614.29% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $10.52 | +470.34% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $6 | $0.58 | +928.81% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $4.08 | +145.10% | 3 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $375 → $240 | $0.94 | +25,345.29% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $14 | $0.86 | +1,527.15% | 2 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Speculative Buy | $180 → $80 | $0.53 | +14,994.34% | 1 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $3.94 | +407.61% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.72 | - | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.95 | - | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.26 | +376.19% | 1 | Jul 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $7.59 | +176.68% | 1 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $300 | $0.32 | +93,855.53% | 1 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $2.13 | +1,637.09% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $20 | $0.93 | +2,045.46% | 3 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $700.33 | - | 6 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $89 | $72.11 | +23.42% | 2 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | n/a | $120.69 | - | 1 | Sep 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Speculative Buy | $1,000 | $1.34 | +74,526.87% | 1 | Jun 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $336 | $2.24 | +14,900.00% | 1 | May 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $4.22 | +326.54% | 1 | Mar 19, 2020 |
UroGen Pharma
Feb 19, 2025
Assumes: Buy
Price Target: $31
Current: $10.08
Upside: +207.54%
Marker Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $11 → $19
Current: $1.57
Upside: +1,110.19%
Corvus Pharmaceuticals
Sep 16, 2024
Maintains: Buy
Price Target: $12 → $21
Current: $4.19
Upside: +401.19%
Compass Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $5
Current: $2.92
Upside: +71.23%
Acrivon Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $16
Current: $5.54
Upside: +188.81%
Calidi Biotherapeutics
Jun 27, 2024
Initiates: Buy
Price Target: $10
Current: $1.05
Upside: +852.38%
Capricor Therapeutics
May 14, 2024
Maintains: Buy
Price Target: $24 → $25
Current: $15.00
Upside: +66.67%
Spruce Biosciences
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.42
Upside: -
Biodexa Pharmaceuticals
Feb 8, 2024
Initiates: Buy
Price Target: $200
Current: $3.71
Upside: +5,290.84%
PMV Pharmaceuticals
Dec 27, 2023
Initiates: Buy
Price Target: $7
Current: $1.41
Upside: +396.45%
Oct 10, 2023
Initiates: Buy
Price Target: $10
Current: $1.40
Upside: +614.29%
Sep 22, 2023
Initiates: Buy
Price Target: $60
Current: $10.52
Upside: +470.34%
Aug 14, 2023
Maintains: Buy
Price Target: $10 → $6
Current: $0.58
Upside: +928.81%
Jun 5, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $4.08
Upside: +145.10%
May 16, 2023
Maintains: Buy
Price Target: $375 → $240
Current: $0.94
Upside: +25,345.29%
Apr 28, 2023
Maintains: Buy
Price Target: $8 → $14
Current: $0.86
Upside: +1,527.15%
Apr 4, 2023
Maintains: Speculative Buy
Price Target: $180 → $80
Current: $0.53
Upside: +14,994.34%
Mar 7, 2023
Initiates: Buy
Price Target: $20
Current: $3.94
Upside: +407.61%
Nov 4, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.72
Upside: -
Aug 23, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.95
Upside: -
Jul 27, 2022
Initiates: Buy
Price Target: $6
Current: $1.26
Upside: +376.19%
Jul 13, 2022
Initiates: Buy
Price Target: $21
Current: $7.59
Upside: +176.68%
May 6, 2022
Initiates: Buy
Price Target: $300
Current: $0.32
Upside: +93,855.53%
May 2, 2022
Initiates: Buy
Price Target: $37
Current: $2.13
Upside: +1,637.09%
Nov 8, 2021
Upgrades: Buy
Price Target: $20
Current: $0.93
Upside: +2,045.46%
Nov 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $700.33
Upside: -
Jul 20, 2021
Upgrades: Buy
Price Target: $89
Current: $72.11
Upside: +23.42%
Sep 30, 2020
Initiates: Hold
Price Target: n/a
Current: $120.69
Upside: -
Jun 16, 2020
Initiates: Speculative Buy
Price Target: $1,000
Current: $1.34
Upside: +74,526.87%
May 21, 2020
Initiates: Buy
Price Target: $336
Current: $2.24
Upside: +14,900.00%
Mar 19, 2020
Initiates: Buy
Price Target: $18
Current: $4.22
Upside: +326.54%